Clinical TrialMay 21, 2026, 05:01 PM
Cardiff Oncology to Present Updated Phase 2 Data for Onvansertib at ASCO
AI Summary
Cardiff Oncology announced it will host an investor webcast on June 3, 2026, to review updated data from its CRDF-004 randomized dose-finding Phase 2 clinical trial. This trial evaluates onvansertib in combination with standard-of-care regimens for first-line RAS-mutated metastatic colorectal cancer. The updated data will first be presented at the 2026 ASCO Annual Meeting on June 2, 2026, building on previous findings from January 2026. Onvansertib, an oral PLK1 inhibitor, is advancing toward a registrational trial, with the 30 mg dose selected for further development.
Key Highlights
- Cardiff Oncology to host investor webcast on June 3, 2026, at 8:30 am ET.
- Updated CRDF-004 Phase 2 data to be presented at ASCO on June 2, 2026, at 9:00 am ET.
- CRDF-004 trial evaluates onvansertib in first-line RAS-mutated metastatic colorectal cancer.
- Onvansertib showed dose-dependent improvements in overall response rate and progression-free survival.
- Company selected 30 mg dose of onvansertib for advancement into a registrational trial.
- Onvansertib is also being evaluated in other cancers through investigator-initiated studies.
Price Impact
More from CRDF